W. Bi

发表

Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo

Shuofeng Yuan, Z. Ye, B. Dang, 2022, Cell Research.

Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants

B. Dang, W. Bi, Guilin Chen, 2022, Journal of virology.

IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies

Lu Lu, Shibo Jiang, L. Su, 2019, PLoS pathogens.

An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells

Q. Wang, Lu Lu, Shibo Jiang, 2020, Science Translational Medicine.

Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy

Q. Wang, Lu Lu, Shibo Jiang, 2015, Journal of Virology.

neutralizing activity in the presence of HIV fusion inhibitor enfuvirtide: a

F. Yu, Qianqian Qi, Qian Wang, 2015 .

Rapid Optical Biosensing of SARS-CoV-2 Spike Proteins in Artificial Samples

Pengbo Wang, S. Bian, Peixi Zhu, 2022, Sensors.

Engineered Trimeric ACE2 Binds and Locks “Three-up” Spike Protein to Potently Inhibit SARS-CoVs and Mutants

Qiang Zhou, Lu Lu, Wei Xu, 2020, bioRxiv.

Receptor Binding Domain Based HIV Vaccines

Lu Lu, Shibo Jiang, Qian Wang, 2015, BioMed research international.

Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection

Qiang Zhou, Lu Lu, Shibo Jiang, 2020, Cell research.